Back to mobile site

Amicus Therapeutics (FOLD) Tops Q1 EPS by 4c ; Provides Outlook

May 9, 2024 7:16 AM EDT

Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.02), $0.04 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $110.4 million versus the consensus estimate of $112.39 million.

Guidance

Total Revenue Growth - 25% to 30%

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

25% to 30%


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings